Arase Therapeutics
Cambridge, United States· Est. 2021
Science-focused oncology company developing first-in-class therapeutics targeting ADP-ribose Hydrolases, novel targets that function therapeutically
Private Company
Total funding raised: $30M
About
Science-focused oncology company developing first-in-class therapeutics targeting ADP-ribose Hydrolases, novel targets that function therapeutically
OncologyImmunology
Funding History
2Total raised:$30M
Series A$25MAug 15, 2023
Seed$5MNov 15, 2021